Get the Stockscreener App
43.39
3.19%
1.34
Moderna Inc stock is traded at $43.39, with a volume of 4.99M.
It is up +3.19% in the last 24 hours and down -18.27% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$42.05
Open:
$42.49
24h Volume:
4.99M
Relative Volume:
0.74
Market Cap:
$16.49B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-4.6406
EPS:
-9.35
Net Cash Flow:
$-3.96B
1W Performance:
+17.46%
1M Performance:
-18.27%
6M Performance:
-73.96%
1Y Performance:
-44.17%
1-Day Range:
$42.08
$43.46
1-Week Range:
$35.96
$46.30
52-Week Range:
$35.80
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
43.39 | 16.49B | 5.06B | -2.22B | -3.96B | -9.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Inc. stock outperforms competitors on strong trading day - MarketWatch
Which is a Better Buy: Moderna or Pfizer? - Baystreet.ca
Why Is Moderna, Inc. (MRNA) Among the Worst Performing Healthcare Stocks in 2024? - Insider Monkey
Moderna price target lowered to $45 from $59 at JPMorgan - Yahoo Finance
The Manufacturers Life Insurance Company Increases Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Announces The Awardees For Its 2024 Australia Fellowship Program, Supporting World-Class mRNA Science In Australia - BioMelbourne Network
Moderna Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Covid-19 Booster Benefits | ModernaWHBF - WHBF - OurQuadCities.com
JPMorgan Chase & Co. Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Moderna's Shares Surge Amid Promising Vaccine Developments and S - GuruFocus.com
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over - The Motley Fool
Moderna, Inc. (MRNA): An Oversold Healthcare Stock to Invest In Now - Yahoo Finance
Moderna’s missteps spotlight PMCPA’s role in upholding pharma ethics - pharmaphorum
Moderna Stock: Optimistic Outlook Despite The Recent Sell-Off (NASDAQ:MRNA) - Seeking Alpha
Prospera Financial Services Inc Decreases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
10 Oversold Healthcare Stocks To Invest In - Insider Monkey
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus.com
Moderna to Present at Upcoming Conferences in December 2024 - Eagle-Tribune
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 29,177 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Charles Schwab Investment Management Inc. Purchases 83,082 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Citigroup Inc. Purchases 138,378 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
StockWatch: Moderna Seeks to Reassure Investors on RFK Jr. - Genetic Engineering & Biotechnology News
Moderna (NASDAQ:MRNA) Stock Price Up 6.2%Still a Buy? - MarketBeat
Moderna Inc. (MRNA): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
B. Metzler seel. Sohn & Co. Holding AG Buys Shares of 22,673 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock Soars After Strong Sales Forecast - Evrim Ağacı
Jefferies says market nears short term “peak RFK negativity", Vaccine makers up - MSN
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Moderna Stock Jumps Following Bullish Sales View at Healthcare Conference - MSN
Goldman Sachs: Moderna, Inc. (NASDAQ:MRNA) Is A Top Growth Investor Stock - Yahoo Finance
Moderna, Gap pop, Tesla drives higher - Yahoo Finance
Jefferies holds Moderna at $50 target, cites RFK concerns - Investing.com
Moderna up 8% as Jefferies says market is close to 'peak RFK negativity' - Seeking Alpha
Moderna's Fresh Blow As RFK Heads To HHSA Tough 2025 May Be In Store (NASDAQ:MRNA) - Seeking Alpha
Banco Santander S.A. Invests $3.55 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. Sued for Securities Law ViolationsContact Levi - GuruFocus.com
MRNA Deadline: MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit - GuruFocus.com
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
Shareholders of Moderna, Inc. Should Contact The Gross Law Firm - GuruFocus.com
Moderna, Inc. Class Action: Levi & Korsinsky Reminds Moderna Inv - GuruFocus.com
Why Is Moderna, Inc. (MRNA) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
John G Ullman & Associates Inc. Buys 38,400 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
US CDC expects COVID and RSV levels to increase in coming weeks - Marketscreener.com
FY2025 EPS Estimates for Moderna Decreased by Analyst - MarketBeat
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View - MSN
Moderna initiated with a Hold at Berenberg - Yahoo Finance
Moderna's stock decline after RFK Jr's appointment makes an "attractive entry point": Piper Sandler - MSN
BioNTech started at buy, Moderna at hold by Berenberg (NASDAQ:BNTX) - Seeking Alpha
Today's Top Stocks: HSIC, Moderna, Uber and More - Baystreet.ca
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):